Baseline NT-ProBNP level predicts success of cardioversion of atrial fibrillation with flecainide

Background Patients with acute-onset symptomatic atrial fibrillation (AF) can be treated with flecainide. However, flecainide may induce arrhythmias and/or exaggerate heart failure. Therefore, validated markers to predict the efficacy of flecainide and prevent adverse effects are required. We hypoth...

Full description

Saved in:
Bibliographic Details
Published in:Netherlands heart journal 2015-03, Vol.23 (3), p.182-189
Main Authors: Amin, Ahmad Shoaib, Peters, René H.J., Verstraaten, Maaike, Wilde, Arthur A.M., Buijs, Eugène M.
Format: Article
Language:English
Subjects:
Age
Blood pressure
Cardiac arrhythmia
Cardiology
Cardiovascular disease
Cardioversion
Design Study
Design Study Article
Diabetes
Drug dosages
Electrocardiography
Heart attacks
Heart failure
Heart rate
Hemodynamics
Hypertension
Laboratories
Medical Education
Medicine
Medicine & Public Health
Patients
Plasma
Quality of life
Regression analysis
Sinuses
Statistical significance
Success
Thyroid diseases
Ultrasonic imaging
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Patients with acute-onset symptomatic atrial fibrillation (AF) can be treated with flecainide. However, flecainide may induce arrhythmias and/or exaggerate heart failure. Therefore, validated markers to predict the efficacy of flecainide and prevent adverse effects are required. We hypothesised that lower NT-proBNP plasma levels correlate with higher success rates of cardioversion with flecainide in patients with AF. Methods In this prospective single-centre study, we included 112 subsequent patients with acute-onset (
ISSN:1568-5888
1876-6250
DOI:10.1007/s12471-015-0659-8